AMSTERDAM, June 5, 2018 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a global
leader in health technology, today announced that it has received
510(k) clearance from the U.S. Food and Drug Administration (FDA)
for its Ingenia Elition 3.0T MR solution and two clinical
applications, Philips Compressed SENSE and 3D APT. This integrated
suite of innovations enables clinicians to perform exams up to 50%
faster [1], increase diagnostic confidence and improve the patient
experience. The first commercial installation of the Philips
Ingenia Elition in the U.S. has recently been completed at Hennepin
Healthcare, a comprehensive healthcare system in Minneapolis.
"Together, the Ingenia Elition and our new clinical applications
make producing high-quality images fast and easy, enabling prompt
diagnosis and setting the stage for effective treatment," said
Arjen Radder, Global Business Leader
for MR at Philips. "We're receiving a strong positive reaction from
our customers as we continue to roll out our all-new Ingenia
digital MR portfolio. It's providing healthcare organizations like
Hennepin Health with innovative solutions that seamlessly connect
data, technology and people to drive the highest quality of
care."
In today's healthcare landscape – where reimbursements are
becoming value-based and chronic conditions lead to more MR
procedures and longer waiting times – there is an ever-increasing
pressure on the radiology department. Philips is responding to
these challenges through the development of new systems and
clinical applications that improve image quality and the patient
and staff experience, as well as operational efficiency.
"To deliver fast, consistent and accurate diagnoses, our staff
need to be supported with technology that gives them the ability to
provide the best patient care, in an efficient and cost-effective
way," said Dr. Chip Truwit, MD,
Chair, Radiology, Hennepin Healthcare. "Philips' Ingenia Elition
plays a critical role in elevating the standard of care for our
patients in imaging and in improving overall operations in our new
imaging center."
Improving diagnostic confidence and the patient
experience
Philips Ingenia Elition and the entire digital MR
portfolio empower a faster, smarter and simpler path to diagnosis –
providing patients and radiologists with the following
benefits:
- Speed of Care – By uniting Philips'
unique dStream digital broadband technology
with Compressed SENSE across its new digital MR portfolio,
radiologists can benefit from up to 50% [1] faster exam times,
increasing throughput and workflow efficiency and resulting in more
time with patients. Additionally, SmartExam analytics enable
automatic planning, scanning and processing of exams that help
improve the entire MR workflow, from image acquisition to reading
preference.
- Confident diagnosis – 3D APT is a contrast-free brain MR
imaging solution that addresses the need for more confident
diagnosis in neuro oncology. By differentiating low-grade and
high-grade gliomas, radiologists have the ability to better
understand a tumor's progression and determine the effect of
treatment [3] [4].
- Improved patient experience – The MR Elition combined
with Philips Ambient Experience and in-bore Connect solution offers
an immersive audio-visual experience may help calm patients,
improving the quality of service for the patient. Herlev Gentofte
University Hospital in Denmark
managed to reduce the number of rescans by up to 70% [5] using the
Ambient Experience in-bore Connect solution with its Ingenia 3.0T
MR, allowing radiologists to handle more patients per day [6]. In
addition to Ambient Experience, Philips' VitalEye brings a
unique patient sensing approach, enabling an intelligent
respiratory signal – allowing routine exam set-up time to occur in
less than a minute [7] – as a part of Philips VitalScreen
technology that allows workflow integration and patient setup.
All-new Ingenia digital MR portfolio
The Ingenia Elition is part of Philips' all-new Ingenia digital
MR portfolio, which supports radiology departments to enhance
productivity, improving the patient and staff experience, while
delivering better value-based care through improved patient
outcomes at lower costs. In addition to receiving U.S. FDA approval
the Ingenia Elition 3.0T is also available for sale in Europe.
[1] Using Compressed SENSE technology and compared to Philips
exams without Compressed SENSE
[2] SmartExam is not available to patients with MR Conditional
implants
[3] Togao et al. (2014) Neuro-Oncology
[4] Park KJ et al. (2016) European Radiology
[5] Results from case studies are not predictive of results in
other cases. Results in other cases may vary
[6] Compared to the average of the other five Philips MR scanners
without Ambient Experience and In-bore Connect. Results from case
studies are not predictive of results in other studies. Results in
other cases may vary
[7] Based on in-house testing
For further information, please contact:
Mark Groves
Philips Group Press Office
Tel.: +31 631 639 916
E-mail: mark.groves@philips.com
About Royal
Philips
Royal Philips
(NYSE: PHG, AEX: PHIA) is a leading health technology company
focused on improving people's health and enabling better outcomes
across the health continuum from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to deliver
integrated solutions. Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, image-guided therapy, patient monitoring and
health informatics, as well as in consumer health and home care.
Philips generated 2017 sales of EUR 17.8
billion and employs approximately 74,000 employees with
sales and services in more than 100 countries. News about Philips
can be found at http://www.philips.com/newscenter.
View original content with
multimedia:http://www.prnewswire.com/news-releases/philips-receives-us-fda-510k-clearance-for-its-ingenia-elition-mr-solution-300659808.html
SOURCE Royal Philips